Pregnancy, Heparin and Osteoporosis

References
1 Griffith GC, Nichols Jr G, Asher JD, Flanagan B. Heparin osteoporosis. J Am Med Assoc 1965; 193: 91-4.
2 Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168: 1265-70.
3 Dahlman T, Sjöberg HE, Hellgren M, Bucht E. Calcium homeostasis in pregnancy during long-term heparin treatment. Br J Obstet Gynaecol 1992; 99: 412-6.
4 Dahlman TC, Sjöberg HE, Ringertz H. Bone mineral density during longterm prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994; 170: 1315-20.
5 Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996; 75: 254-7.
6 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-7.
7 Barbour LA, Kick SD, Steiner JF, LoVerde ME, Heddleston LN, Lear JL, Baron AE, Barton PL. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170: 862-9.
8 Howell R, Fidler J, Letsky E, de Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br J Obstet Gynaecol 1983; 90: 1124-8.
9 Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, MacGillavry MR, Hamulyak K, Theunissen IM, Hunt BJ, Buller HR. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72.
10 Backos M, Rai R, Thomas E, Murphy M, Dore C, Regan L. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14: 2876-80.
11 Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996; 65: 171-4.
12 Pettilä V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or low-molecular-weight heparin. Thromb Haemost 2002; 87: 182-6.
13 Pettilä V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999; 96: 275-82.
14 Grassman ED, Leya F, Fareed J, Lewis BE, Bacher P, Loeb HS, Moran JF. A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty. J Invasive Cardiol 2001; 13: 723-8.
15 Lai KN, Ho K, Cheung RC, Lit LC, Lee SK, Fung KS, Tong MK, Lam CW. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs 2001; 24: 447-55.
16 Hunt BJ, Doughty H-A, Majumdar G, Copplestone A, Kerslake S, Buchanan N, Hughes G, Khamashta M. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.
17 Guglielmi G, Glüer CC, Majumdar S, Blunt BA, Genant HK. Current methods and advances in bone densitometry. Eur Radiol 1995; 05: 129-39.